Ovid Therapeutics Inc reports results for the quarter ended in September - Earnings Summary

Ovid Therapeutics

08/11/2022 14:33

* Ovid Therapeutics Inc  OVID.OQ  reported a quarterly
adjusted
loss of 17 cents​​ per share for the quarter ended in September.
The mean expectation of four analysts for the quarter was for a
loss of 21 cents per share.
    * Revenue was $11.10 million​; analysts expected zero. 
    * Ovid Therapeutics Inc's reported EPS for the quarter was a
loss
of 17 cents​.
    * The mean earnings estimate of analysts had risen by
about 7.8%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Ovid Therapeutics Inc shares had fallen by 21.7% this
quarter and lost 55.1% so far this year.
    * The company reported a quarterly loss of $11.97 million.
    * Wall Street's median 12-month price target for Ovid
Therapeutics
Inc is $4.75 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
8 at 02:32 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.21          -0.17          Beat
 Jun. 30 2022      -0.25          -0.21          Beat
 Mar. 31 2022      -0.21          -0.23          Missed
 Dec. 31 2021      -0.16          -0.10          Beat